321 results about "Anxiety disorder" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and / or measures of depression (HDRS or BDI scores) and / or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present disclosure provides a method of treating a symptom or preventing a symptom of generalized anxiety disorder comprising administering an orally disintegrating tablet comprising LSD, or a salt thereof, to a subject in need thereof.

The invention belongs to the technical field of microorganisms, and relates to high-activity plant lactobacillus KL100 for relieving anxiety and depression and application of the high-activity plant lactobacillus KL100. The plant lactobacillus provided by the invention is KL100, is preserved in the China General Microbiological Culture Collection Center (CGMCC), has a preservation number of CGMCC No.27192, and is classified and named as the plant lactobacillus. The plant lactobacillus is KL100, has a good gastrointestinal passing rate, shows a breeding characteristic in the stomach after being embedded, is improved in cholate-resistant survival rate, and can be used for preparing the plant lactobacillus. According to the application disclosed by the invention, the expression of IL-1beta and TNF-alpha in a mouse body can be effectively reduced, the expression of IL-10 can be improved, and the secretion of 5-hydroxytryptamine by chromaffin cells in intestinal tracts can be promoted, so that anxiety and depression can be relieved, the strain resource is expanded, the development of the biological medicine field is promoted, and a new direction is provided for treating anxiety and depression.

The invention discloses a traditional Chinese medicine composition for treating depression as well as a preparation method and application of the traditional Chinese medicine composition. The preparation method comprises the following steps: weighing vinegar-processed rhizoma cyperi, ligusticum wallichii, fried rhizoma atractylodis, fried medicated leaven and fried fructus gardeniae which are equal in mass; crushing and sieving the vinegar rhizoma cyperi, the ligusticum wallichii, the fried rhizoma atractylodis and the fried medicated leaven to obtain traditional Chinese medicine powder; placing the traditional Chinese medicine powder in a 60-80% ethanol solution for decoction extraction, filtering, collecting filtrate, repeatedly extracting for 2-4 times, merging the filtrate, concentrating and drying to obtain thick paste; the fried cape jasmine is smashed and sieved, cape jasmine powder is obtained, then the cape jasmine powder and the thick paste are mixed, and the traditional Chinese medicine composition for treating depression is obtained. The preparation method disclosed by the invention can be used for efficiently and fully extracting active ingredients, such as ligustilide, atractydin I and alpha-cyperone, in the traditional Chinese medicine raw materials to obtain a new extract which is excellent in medicine effect, clear in ingredients and free from obvious toxic and side effects, and is expected to be developed as a novel medicine for improving and / or treating depression and anxiety disorder.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

Methods, systems and devices for reducing anxiety, including increasing relaxation and / or calm. In some variations these methods may include reducing anxiety, increase relaxation and / or calm by non-invasive temperature regulation of the frontal cortex prior to and / or during sleep. The subject may have an anxiety disorder, or may not have a diagnosed anxiety disorder.

The invention provides a method for constructing a chronic unpredictable negative stress model, the chronic unpredictable negative stress model and application of the chronic unpredictable negative stress model in mental disease research, and belongs to the field of brain organ in-vitro model construction. Through dual verification of a microelectrode array and single cell sequencing, an in-vitro brain organ model capable of simulating chronic unpredictable negative stress core characteristics is successfully constructed, and a potential neural network function reconstruction mechanism and a cell molecule basis of the in-vitro brain organ model are disclosed. The comprehensive research normal form breaks through the limitation of a traditional single technology platform, and an accurate and efficient innovative research platform highly related to human is provided for pathogenesis research of mental diseases, especially chronic stress related diseases such as depression and anxiety and development of novel treatment strategies.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The present invention relates to the use of STING agonists in depression or anxiety disorders. Specifically, the compound disclosed by the invention is described in the specification, and the compound disclosed by the invention has an excellent prevention and / or treatment effect on depression and / or anxiety disorder.

The invention discloses a traditional Chinese medicine composition for treating breast cancer complicated with anxiety disorder as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is mainly prepared from the following raw material medicines: astragalus membranaceus, herba epimedii, ligusticum wallichii, semen boitae, acanthopanax, rhizoma drynariae, selfheal, arisaema cum bile, turtle shell, nigrum fruit, salvia chinensis and artemisia apiacea. The invention further discloses a preparation method of the traditional Chinese medicine composition, a pharmaceutical preparation and application. Pharmacodynamic experiments prove that the traditional Chinese medicine composition can remarkably inhibit tumor growth of anxiety tumor-bearing mice and improve anxiety behavioral indexes, achieves dual treatment targets of tumor resistance and emotion regulation, and is particularly suitable for middle and advanced breast cancer combined anxiety patient groups needing long-term treatment.

The present invention generally provides methods and compositions for the treatment of Parkinson's disease and depression and / or anxiety. The invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce L-DOPA.

The invention relates to a VR meditation course framework design method based on cognitive enhancement, and the method comprises the steps: S1, evaluating the anxiety level, meditation concentration degree and exercise ability of teenagers according to a plurality of scale systems, and customizing exercise and meditation guidance parameters for a user according to an evaluation result; s2, constructing an interactive physical exercise scene, and dynamically and accurately adjusting the duration and complexity of exercise according to preset guidance parameters; s3, customizing deep breathing training and guiding meditation courses; and S4, evaluating the performance of the user in the previous two stages according to the exercise quality of the exercise and the meditation depth questionnaire, and providing guidance for subsequent courses by an obtained quality score. The method provided by the invention can provide evaluation guidance for the teenagers with depression, and provides data support and a new means for relieving anxiety symptoms of the teenagers.

The invention relates to the technical field of medical instruments, in particular to a multi-mode biological feedback ear vagus nerve self-adaptive stimulation device and method.The device comprises a host, a stimulation electrode, a signal collection bracelet and an electroencephalogram collection module, and the host comprises core hardware configuration and a power management system; the signal acquisition bracelet comprises an ECG module, a PPG module, a GSR module, a six-axis acceleration sensor and the like. The ear vagus nerve stimulation parameter can be dynamically adjusted through real-time analysis of multi-mode data such as electrocardio, electroencephalogram, heart rate variability, respiration-heart rate synchronism and emotional state, personalized precise treatment is achieved, meanwhile, the wearing comfort and the durability of the device are improved, and the application range is wide. The traditional Chinese medicine composition can be used for auxiliary treatment of various diseases such as inflammatory bowel disease, epilepsy, chronic insomnia, depression, chronic pain, anxiety disorder, post-traumatic stress disorder and autonomic nerve dysfunction, and the functions of a nervous system are adjusted and the symptoms of a patient are improved by accurately stimulating the vagus nerve in the auricular concha area.

The invention relates to particular prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one, in free or pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and / or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.

The invention relates to application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for relieving depression or anxiety. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The invention develops a brand new application of the bifidobacterium animalis subsp. Lactis BLa80 strain, namely, the bifidobacterium animalis subsp. Lactis BLa80 strain is used for relieving depression or anxiety symptoms, specifically, the bifidobacterium animalis subsp. Lactis BLa80 strain can stimulate RIN14B cells to secrete 5-HT, can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety, can relieve hyperfunction of hypothalamic-pituitary-adrenal axis (HPA axis), and can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety. The inflammatory response of mice with depression and anxiety is relieved, the expression level of brain-derived neurotrophic factors in hippocampus of the mice with depression and anxiety is improved, the abundance of intestinal beneficial flora of the mice with depression and anxiety is improved, and the diversity of intestinal flora is increased.

The invention discloses an intestinal flora marker and application thereof in diagnosis and treatment of anxiety disorder. According to the present invention, the intestinal flora marker comprises a specific strain Lacnospiraceae bacterium.1 of the genus of Horsespirillum, Odorobacter splanchnicus, Coprococcus dexterous, and Clostridium aldenense, and the intestinal flora marker comprises a specific strain Lacnospiraceae bacterium.1 of the genus of Horsespirillum, Odorobacter splanchnicus, Coprococcus dexterous, and Clostridium aldenense, the ROC curve analysis of the intestinal flora marker as a detection variable of anxiety disorder has high specificity and sensitivity, so that the intestinal flora marker can be used as a detection marker to be applied to diagnosis of anxiety disorder patients. The intestinal flora marker disclosed by the invention is used as a detection marker of anxiety disorder, is completely noninvasive and is high in accuracy.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention relates to the technical field of patient psychological nursing, in particular to a neurology patient psychological nursing analysis system and method based on an intelligent chip, and the method comprises the steps: analyzing the difference degree of the physiological characteristics of an anxiety patient before and after an operation based on preoperative physiological characteristic data and postoperative physiological characteristic data; based on the symptom reaction data and the operation data of the anxiety patient, analyzing the operation complexity of the anxiety patient; according to the physiological feature difference degree analysis result before and after the operation and the operation complexity degree analysis result, the psychological stress risk of the anxiety disorder patient is evaluated; according to the psychological stress risk assessment result, patient psychological nursing early warning is given to medical staff, by accurately quantifying the psychological stress risk, the high-risk patient can be recognized in the early stage, postoperative acute anxiety, delirium and other complications are avoided, and the operation safety and rehabilitation quality are remarkably improved.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.